High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma

NuklearMedizin

Volumn 38, Issue 8, 1999, Pages 337-340

  Franzius, Christiane ^a   Bielack, S ^a   Sciuk, J ^a   Vollet, B ^a   Jurgens H ^a   Schober, O ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Autologous peripheral blood stem cell reinfusion; High activity samarium 153 EDTMP therapy; Osteosarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LEXIDRONAM SAMARIUM SM 153;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INOPERABLE CANCER; LUNG METASTASIS; OSTEOSARCOMA; PERIPHERAL BLOOD STEM CELL; POSITRON EMISSION TOMOGRAPHY; STEM CELL TRANSPLANTATION;

EID: 0032796890     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1632233     Document Type: Article

References (13)

1. Albrecht MR, Henze G, Rühl U, Habermalz HJ. Osteosarcoma - A Radioresistent Tumor? Long-Term Evaluation After Multidrug Chemotherapy and Definitive Irradiation. Med Pediatr Oncol 1996; 27: 314.
2. Anderson PM. Sm-153-EDTMP therapy with stem cell support in patients. In: Towards the Eradication of Osteosarcoma Metastases. Bruland OS (ed.). The Norwegian Radium Hospital, Oslo, Norway 1998; 87-8.
3. Bruland OS, Pihl A. On the Current Management of Osteosarcoma. A Critical Evaluation and a Proposal for a Modified Treatment Strategy. Eur J Cancer 1997; 33: 1725-31.
4. Bruland OS, Skretting A, Solheim OP, Aas M. Targeted Radiotherapy of Osteosarcoma using Sm-153-EDTMP. A new promising approach. Acta Oncologica 1996; 35: 381-4.
5. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDT-MP: Pharmacokinetic, Toxicity and Pain Response Using an Escalating Dose Schedule in Treatment of Metastatic Bone Cancer. J Nucl Med 1992; 33: 1451-8.
6. Franzius C, Sciuk J, Schober O. Radionuclide Therapy of Bone Tumors: From Palliative to Curative Approach. Nuklearmedizin 1999 (8); Editorial.
7. Fuchs K, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-9.
8. Gaitan-Yanguas M. A study of the response of osteogenic sarcoma and adjacent normal tissue to radiation. Int J Radiat Oncol Biol Phys 1981; 7: 593-5.
9. Lattimer JC, Corwin Jr. LA, Stapleton J, Volkert WA, Ehrhardt GJ, Ketring AR, Anderson SK, Simon J, Goeckeler WF. Clinical and Clinicopathologic Response of Canine Bone Tumor Patients to Treatment with Samarium-153-EDTMP. J Nucl Med 1990; 31: 1316-25.
10. Logan KW, Volkert WA, Holmes RA. Radiation Dose Calculations in Persons Receiving Injection of Samarium-153 EDTMP. J Nucl Med 1987; 28: 505-9.
11. Moe L, Boysen M, Aas M, Lonaas L, Gamlem H, Bruland O. Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. J Small Anim Pract 1996; 37: 241-6.
12. van Rendsburg AJ, Alberts AS, Louw WKA. Quantifying the Radiation Dosage to Individual Skeletal Lesions Treated with Samarium-153-EDTMP. J Nucl Med 1998; 39: 2110-5.
13. Winderen M, Kjoenniksen I, Fodstad O. Pronounced Therapeutic Effect of Samarium-153-Ethylene-diamine-tetramethylene Phosphonate in an Orthotopic Human Osteosarcoma Tibial Tumor Model. J Nat Cancer Inst 1995; 87: 221-2.